Vaccination against intracellular pathogens requires generation of a pool of memory T cells able to respond upon infection and mediate either killing of the infected cell or induce killing mechanisms in the infected cell. T cell-inducing vaccines must aim to target the antigen to antigen-presenting cells (APCs) so that it can be presented on MHC molecules on the cell surface. Methods to do this include making use of vectors such as plasmid DNA or viruses, live attenuated pathogens or subunit vaccines targeted and enhanced using adjuvants. The choice of approach should be guided by the phenotype and localization of the desired T cell response. This review will discuss current approaches in the pipeline for the development of T cell-inducing vaccines, including vectored, live attenuated, and subunit vaccines. 
Introduction
Diseases for which vaccination has been successful are caused by pathogens that are either extracellular, spend a significant part of their lifecycle outside the cell, or whose disease is mediated through toxins. Vaccination against intracellular pathogens, however, including those causing diseases such as tuberculosis (TB), tularemia, chlamydia and leishmaniasis, has proven more difficult [1] [2] [3] [4] . Given their intracellular nature, immunity against these pathogens is primarily T cell-mediated, a fact that is wellestablished. The role of B cells in many of these infections is still debated, however most studies demonstrate that while B cells may contribute to protection, B cell immunity is not central to pathogen control [5, 6] . Thus, in the context of vaccine-induced immunity, it is becoming apparent that the phenotype and localization of antigenspecific T cells is essential to vaccine efficacy. For example, there is substantial new evidence supporting a role for T helper-17 (Th17) cells in vaccine-mediated immunity against TB [7 ,8,9 ]. However, given the propensity for high levels of interleukin (IL)-17 to induce inflammation [10, 11 ], development of such a regime for use in humans needs to be carefully validated. Thus, one of the major challenges faced in the development of T cell-inducing vaccines is the generation of a persistent pool of appropriate memory T cells localized at the correct anatomical site for optimal pathogen clearance via a safe delivery system. This review will discuss current approaches in the pipeline for the development of T cellinducing vaccines, including vectored, live attenuated, and subunit vaccines.
Vectored vaccines
Vectored vaccines make use of DNA-based constructs in the form of viruses, plasmids or bacteria to express antigenic genes from the pathogen of interest, for antigen presentation in the host. Furthermore, cell death caused by vector infection promotes antigen presentation through uptake of dead cells by antigen-presenting cells (APCs). Vectors in the form of viruses or bacteria are selfadjuvanting, enhancing antigen presentation by engaging pattern-recognition receptors (PRRs). The most common viral vectors in clinical trials are attenuated adenoviruses and Modified Vaccinia Virus Ankara (MVA). Adenoviruses are able to replicate in human cells, leading to prolonged antigen expression and enhanced exposure of T cells to APCs [12] . Adenoviruses signal through the intracellular CpG-sensing TLR9, inducing both cellular and humoral responses [13, 14] . However, one drawback to the use of adenoviruses is human is that pre-exposure to the viruses results in an adenovirus-specific memory response (anti-vector immunity), leading to early viral clearance, loss of prolonged gene expression and lower immunogenicity [15] . In an attempt to overcome antivector immunity, novel vectors using chimpanzeespecific adenoviruses are in development, which exhibit low pre-existing anti-vector immunity in humans [16, 17] . These studies together suggest that induction of optimal polyfunctional T cell responses is crucial for effective vaccine design against intracellular pathogens.
DNA vaccines in the form of plasmids expressing pathogen-derived genes have been in development for a number of years for several diseases, including malaria and influenza [28, 29] . A factor that has stunted their progress through clinical trials, however, is low immunogenicity. A recent approach to overcome this is the use of electroporation, thus increasing passage of the vaccine into the cell, at the same time increasing APC recruitment to the site of vaccination [30] . Currently, no DNA vaccines with electroporation against intracellular pathogens have reached clinical trials, however the approach has been employed in both HIV and influenza vaccines in mice, with results showing increased immunogenicity following electroporation [31, 32] .
Thus, vectored vaccines represent an efficient method of targeting an immune response to antigens of interest. It is important to note that most of the immune responses documented in the past have considered induction of T cells that produce IFN-g, IL-2 and TNF-a. However, since IL-17 has recently been implicated in protection against several intracellular pathogens [33] , perhaps attenuated strains of IL-17-inducing pathogens, such as Bordetella pertussis and Salmonella spp., may also be considered as vectors in the future.
Live attenuated vaccines
The advantages of using live attenuated vaccines are the self-adjuvanting effect of the attenuated pathogen and expression of most of the pathogen genome, providing a wide range of antigenic targets. Several live attenuated vaccines against intracellular pathogens are in development. With the aim of developing an alternative to BCG, three attenuated forms of mycobacterial species have shown efficacy in pre-clinical studies. In order to improve the immunogenicity of BCG through inducing CD8 + T cells, BCGDureChly + was engineered to express the membrane-lysing agent listeriolysin from L. monocytogenes. Urease C was also deleted from the genome, allowing acidification of the phagolysosome for optimal conditions for listeriolysin activity. This allows BCG escape from the phagolysosome, leading to increased antigen presentation. In a mouse model of TB, BCGDureChly + confers improved protection over wild-type BCG [34, 35] . This is associated with increased production of IFN-g and IL-17 as well as polyfunctional IL-2
+ T in the lungs, and increased IL-17 in the spleen compared to BCG immunization. IKEPLUS is an attenuated form of Mycobacterium smegmatis in which the endogenous esx-3 secretion system has been replaced by the Mtb equivalent [36 ] , and when used as a vaccine against Mtb challenge in the mouse model, it is both immunogenic and protective [36 ] . In adoptive transfer experiments, CD4
+ rather than CD8 + T cells were found to confer protection, with IKEPLUS inducing higher numbers of cells producing IFN-g, IL-2 and TNF-a than BCG [36 ] . Finally, SO2 is an attenuated Mtb lacking PhoP, which forms part of the two-component system PhoP/PhoR essential to virulence [37] . When used as a vaccine in both mouse and guinea pig models of TB, SO2 induces increased total CD4 + and CD8 + T cell numbers in the lymph nodes, as well as increased IFN-g production [38, 39] . In a challenge model, SO2 confers improved protection over BCG, suggesting that use of a vaccine strain that is genetically similar to the challenge strain and more virulent than BCG may be beneficial to inducing protective responses.
That protection against tularemia requires IL-17 is highlighted in two separate studies using attenuated forms of the virulent SchuS4 F. tularensis strain. These were administered either intradermally only [40] , or intradermally or intranasally [41 ] as live attenuated vaccines. The attenuated SchuS4 strains induced improved protection over LVS and was associated with increased IL-17 production in the lungs of challenged mice [40] , however intranasal delivery did not improve on intranasal challenge [41 ] . This is in contrast to results from Mtb vaccine studies in which intranasal delivery confers improved protection over parenteral delivery [7 ,8] , suggesting that the site of T cell induction for optimal responses may differ between pathogens. Provided there is no risk of reversion, live attenuated vaccines represent a valid approach for T cell-inducing vaccines given the potential for induction of an immune response to a broad range of antigens.
Subunit vaccines
A final approach to vaccination against intracellular pathogens is subunit vaccines, composed of peptides, proteins or non-protein components of the pathogen. In order for subunit vaccines to be successful, they must be targeted to the correct APC to ensure efficient uptake and presentation. Cells such as dendritic cells (DC) can be targeted through liposomes, which surround the antigen, escorting its delivery inside the cell. The outcome of the immune response to the subunit alone depends on the inherent immunogenicity of the subunit itself, however the immunogenicity of the vaccine can be improved by co-administration with an adjuvant. Currently, the only two adjuvants in use in licensed vaccines in humans are alum and monophospholipid-A (MPL), although several are in development; alum is known to be beneficial for antibody-inducing vaccines and stimulates a Th2-skewed response, whereas MPL induces a Th1 bias. It should be noted that the choice of adjuvant may adversely affect the desired outcome; indeed, the alum included in several Expanded Programme on Immunisation (EPI) schedule vaccines has been shown to reduce the immunogenicity of MVA85A when MVA85A was delivered concurrently with the EPI vaccines [42] .
Most novel vaccines in development against leishmaniasis are protein subunit vaccines targeting various antigens.
Kaur et al. demonstrate protective efficacy in the mouse model of Leishmania donovani infection of a subunit vaccine comprising gp63 with hsp70 as the adjuvant, enhancing IFN-g and reducing IL-4 and IL-10 levels [43] . Similarly, recent studies using gp63 delivered in cationic liposomes with the adjuvant combination MPL and trehalose dimycolate showed protective efficacy and IFN-g induction in the mouse model following challenge with L. donovani [44] . Results from these experiments highlight the adjuvanting effect of targeting APCs with liposomes. Another leishmania vaccine administered with MPL includes the polyprotein LEISH-F1, which is composed of three conserved leishmanial proteins: LeIF, TSA and LmSTI1. LEISH-F1 has been shown to be safe and immunogenic in humans, inducing IFN-g responses above background in naïve individuals, those with a history of Leishmania exposure, and infected individuals undergoing chemotherapy [45] [46] [47] [48] .
Subunit vaccines against tularemia are also in development. Here, the heat shock protein DnaK was combined with the F. tularensis surface protein Tul4 and administered to mice intranasally along with the adjuvant GPI [49] . The vaccine was shown to induce antigen-specific IFN-g and IL-17 responses, as well as antibodies, and afforded 80% efficacy following challenge with a lethal dose of LVS, and reduced dissemination to liver and spleen. Another approach used to adjuvant subunit vaccines is the use of proteosomes -vesicles formed through protein-protein interactions that have been shown to be immunogenic in a similar manner to liposomes. Such an approach has been used for vaccination against Chlamydia spp. using the major outer membrane protein (MOMP). In mice, MOMP formulated as a proteosome and delivered intramuscularly and subcutaneously, induces both antibody and IFN-g production, and protection following challenge with Chlamydia muridarum [50] .
Finally, subunit vaccines can also be used as a boost for vectored or live vaccines in heterologous prime-boost strategies. Such approaches have the advantage of inducing an immunogenic response at the time of primary vaccination, whilst overcoming the problem of anti-vector immunity in the boost. Indeed, the subunit TB vaccine H56, composed of three proteins expressed during both active and latent Mtb infection has shown both efficacy and immunogenicity in mice and non-human primate (NHP) disease models when used as a boost for BCG delivered along with the novel adjuvants IC31 (NHP) or CAF01 (mice) [51, 52] .
Concluding remarks
From the literature reviewed here, it seems clear that the overriding hurdle is the ability to induce a protective T cell phenotype that localizes to the correct organ and translates from animal studies to humans. Strategies for developing vaccines against intracellular pathogens aim to deliver antigen to APCs in order to induce antigen presentation (Figure 1 ). The key variable is the type of adaptive response required for pathogen clearance, which can be modulated by the mechanism of antigen delivery. References and recommended reading 
